We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

14 hedge funds and large institutions have $2.09M invested in AIM ImmunoTech in 2013 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

11% more capital invested

Capital invested by funds: $1.89M → $2.09M (+$202K)

8% more funds holding

Funds holding: 13 → 14 (+1)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
14
Holders Change
+1
Holders Change %
+7.69%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
+$75.6K
2
Renaissance Technologies
Renaissance Technologies
New York
+$63K
3
Citadel Advisors
Citadel Advisors
Florida
+$25.2K

Top Sellers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
-$30K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$25.2K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$12.6K
4
CS
Credit Suisse
Switzerland
-$4K
5
Two Sigma Investments
Two Sigma Investments
New York
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$856K – – –
BIT
2
BlackRock Institutional Trust
California
$522K – – –
Jacobs Levy Equity Management
3
Jacobs Levy Equity Management
New Jersey
$189K -$25.2K -2 -12%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$133K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$86K +$63K +5 +250%
Deutsche Bank
6
Deutsche Bank
Germany
$76K +$75.6K +6 New
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
$68K -$12.6K -1 -17%
Northern Trust
8
Northern Trust
Illinois
$57K – – –
Citadel Advisors
9
Citadel Advisors
Florida
$25K +$25.2K +2 New
State Street
10
State Street
Massachusetts
$21K – – –
GC
11
Guggenheim Capital
Illinois
$15K – – –
VKH
12
Virtu KCG Holdings
New York
$13K +$12.6K +1 New
Bank of America
13
Bank of America
North Carolina
$7K – – –
JIC
14
Joel Isaacson & Co
New York
$7K – – –
Goldman Sachs
15
Goldman Sachs
New York
$5K – – –
ICAS
16
Investors Capital Advisory Services
Massachusetts
$3K – – –
BA
17
BlackRock Advisors
Delaware
$2K – – –
U
18
UBS
Switzerland
$2K – – –
Wells Fargo
19
Wells Fargo
California
$2K – – –
Bank of New York Mellon
20
Bank of New York Mellon
New York
– -$30K -3 Closed
CS
21
Credit Suisse
Switzerland
– -$4K – –
Two Sigma Investments
22
Two Sigma Investments
New York
– -$3K – –

AIM Hedge Fund Activity: Q3 2013 in Review

14 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q3 2013, worth a combined $2.09M — up 11% from $1.89M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new AIM positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Deutsche Bank, opening a new position worth an estimated $75.6K. The largest seller was Bank of New York Mellon, exiting entirely with an estimated $30K sold.

  • 14 institutional investors held AIM ImmunoTech (AIM) as of Q3 2013, up from 13 in Q2 2013.
  • Funds reported $2.09M of AIM ImmunoTech stock for Q3 2013, up 11% quarter-over-quarter.
  • 3 funds opened new AIM ImmunoTech positions in Q3 2013 and 1 closed out, a net change of +2 holders.
  • The largest AIM ImmunoTech buyer in Q3 2013 was Deutsche Bank, an estimated $75.6K added.
  • The largest AIM ImmunoTech seller in Q3 2013 was Bank of New York Mellon, an estimated $30K sold.

Based on aggregated 13F filings for Q3 2013.